Oxygenta Pharmaceutical Valuation

Is 524636 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524636 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 524636's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 524636's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524636?

Key metric: As 524636 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 524636. This is calculated by dividing 524636's market cap by their current revenue.
What is 524636's PS Ratio?
PS Ratio	5.9x
Sales	₹463.28m
Market Cap	₹2.72b

524636 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.2x
Enterprise Value/EBITDA	-41.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 524636's PS Ratio compare to its peers?

The above table shows the PS ratio for 524636 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2x
530313 Kimia Biosciences	2.1x	n/a	₹2.3b
SMSLIFE SMS Lifesciences India	1.1x	n/a	₹3.5b
ALPA Alpa Laboratories	2.4x	n/a	₹2.3b
524506 Coral Laboratories	2.5x	n/a	₹2.8b
524636 Oxygenta Pharmaceutical	5.9x	n/a	₹2.7b

Price-To-Sales vs Peers: 524636 is expensive based on its Price-To-Sales Ratio (5.9x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does 524636's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$87.67m
539561 Remedium Lifecare	0.07x	n/a	US$26.84m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.05m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.21m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 524636 is expensive based on its Price-To-Sales Ratio (5.9x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is 524636's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524636 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524636's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

0.8%

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

3.5%

52.4%